Glenmark Pharmaceuticals Inc., USA, affiliated to India-based Glenmark Pharmaceuticals Ltd., announced Tuesday the launch of Vancomycin Hydrochloride for Injection USP in single-dose vials of 750 mg/vial, 1.25 g/vial and 1.5 g/vial.
The company noted that its Vancomycin Hydrochloride for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial of Mylan Laboratories Limited, NDA 209481.
According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection market achieved annual sales of approximately $39.3 million.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "We are excited to announce the launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial), adding another quality product to our institutional portfolio."
In India, on the NSE, Glenmark shares closed Tuesday's trading at 1,509.20 Indian Rupees, down 2.07%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.